Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.
Autor: | Melzer-Cohen C; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel., Chodick G; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Naftelberg S; Medical Affairs, Novo Nordisk, Kefar Sava, Israel., Shehadeh N; Institute of Endocrinology, Diabetes and Metabolism, Rambam Campus, Haifa, Israel., Karasik A; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel. karasik@post.tau.ac.il.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. karasik@post.tau.ac.il.; Institute of Endocrinology,, Chaim Sheba Medical Center, Tel Hashomer, Israel. karasik@post.tau.ac.il. |
---|---|
Jazyk: | angličtina |
Zdroj: | Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2020 Jan; Vol. 11 (1), pp. 185-196. Date of Electronic Publication: 2019 Dec 05. |
DOI: | 10.1007/s13300-019-00725-9 |
Abstrakt: | Introduction: Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination (FRC) of basal insulin and glucagon-like protein-1 receptor agonist (GLP-1 RA) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (T2DM) in both randomized controlled trials and real-world studies. The impact of adherence to this medication and its effect on patients with T2DM who switch from loose-dose combination therapy to a FRC of insulin and GLP-1RA have not yet been reported. We have examined the metabolic effects and adherence to this medication in a real-life setting, in T2DM patients who initiated IDegLira therapy after being treated with other glucose-lowering drugs. Methods: This is a retrospective observational study of adult T2DM patients managed by the Maccabi Healthcare Services (Israel) who initiated IDegLira and persisted with therapy for 180 days between July 2017 and August 2018. Mean glycated hemoglobin (HbA Results: A total of 413 patients who persisted with IDegLira therapy for at least 180 days were evaluated as a per protocol group. A significant mean reduction in HbA Conclusion: In a real-world setting, the use of IDegLira was associated with improved glycemic control and adherence to therapy. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |